Enhertu Early Breast Cancer: FDA Priority Revie...

By João L. Carapinha

March 10, 2026

Enhertu (trastuzumab deruxtecan), developed by ...
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
EMA’s mCombriax Vaccine Recommendation
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in A...
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
SAHPRA GMP Compliance: Addressing Allegations Against Adcock Ingram’s C...
Economic Impact of Industry Clinical Trials in Europe
Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency...